Document Detail

Efficacy of deoxycholate amphotericin B and unilamellar liposomal amphotericin B in prophylaxis of experimental Aspergillus fumigatus endocarditis.
MedLine Citation:
PMID:  9374975     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate and compare in vivo the protective efficacy of unilamellar liposomal amphotericin B (L-AmB) with that of deoxycholate amphotericin B (D-AmB) in experimental endocarditis.
MATERIAL AND METHODS: In the rabbit model of experimental Aspergillus fumigatus endocarditis, two doses of each antifungal agent (1.5 mg/kg each) were administered intravenously at 4 hours and at 30 minutes before challenge with an inoculum of A. fumigatus. Three days later, the animals were sacrificed, and the aortic vegetations were analyzed.
RESULTS: All 19 animals that did not receive chemoprophylaxis acquired endocarditis. In contrast, endocarditis developed in 2 of 10 animals pretreated with D-AmB (P < 0.01) and 3 of 8 animals pretreated with L-AmB (P < 0.01). Both D-AmB and L-AmB prevented the development of endocarditis due to A. fumigatus and decreased the concentration of fungi in the aortic vegetations by more than 1 log10.
CONCLUSION: In the rabbit experimental model of Aspergillus endocarditis, D-AmB and L-AmB were equally effective in reducing the incidence of the infection and the tissue burden of fungi.
E Mylonakis; G Chalevelakis; G Saroglou; P Danias; A D Argyropoulou; O Paniara; S A Raptis
Related Documents :
8877535 - Liposomal amphotericin b (ambisome) reduces dissemination of infection as compared with...
20208075 - Response to azolic antifungal agents for treating feline sporotrichosis.
17372685 - Advances in targeting drug delivery to glomerular mesangial cells by long circulating c...
18397335 - Therapeutic and prophylactic efficacy of aminocandin (ip960) against disseminated candi...
16387745 - Beta-carotene supplementation attenuates cardiac remodeling induced by one-month tobacc...
23011175 - Pharmacokinetics of cyclosporine a conversion from twice-daily infusion to oral adminis...
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  Mayo Clinic proceedings     Volume:  72     ISSN:  0025-6196     ISO Abbreviation:  Mayo Clin. Proc.     Publication Date:  1997 Nov 
Date Detail:
Created Date:  1997-12-11     Completed Date:  1997-12-11     Revised Date:  2013-12-13    
Medline Journal Info:
Nlm Unique ID:  0405543     Medline TA:  Mayo Clin Proc     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1022-7     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amphotericin B / administration & dosage,  therapeutic use*
Antifungal Agents / administration & dosage,  therapeutic use*
Aspergillosis / microbiology*,  prevention & control*
Aspergillus fumigatus / drug effects*
Cholagogues and Choleretics
Deoxycholic Acid
Disease Models, Animal
Endocarditis / microbiology*,  prevention & control*
Reg. No./Substance:
0/Antifungal Agents; 0/Cholagogues and Choleretics; 0/Liposomes; 005990WHZZ/Deoxycholic Acid; 7XU7A7DROE/Amphotericin B

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Are coronary-care unit changes in therapy associated with improved survival of elderly patients with...
Next Document:  Giant cell granulomatous pulmonary and myocardial lesions in necrobiotic xanthogranuloma with parapr...